Validation of Differentially Expressed Brain-Enriched microRNAs in the Plasma of Parkinson’s Disease Patients

Stylianos Ravanidis  
Idryma Iatrobiologikon Ereunon tes Akademias Athenon

Anastasia Bougea  
National and Kapodistrian University of Athens Aiginitio Hospital

Nikolaos Papagiannakis  
National and Kapodistrian University of Athens Aiginitio Hospital

Christos Koros  
National and Kapodistrian University of Athens Aiginitio Hospital

Athina Simitsi  
National and Kapodistrian University of Athens Aiginitio Hospital

Ioanna Pachi  
National and Kapodistrian University of Athens Aiginitio Hospital

Marianthi Breza  
National and Kapodistrian University of Athens Aiginitio Hospital

Leonidas Stefanis  
National and Kapodistrian University of Athens Aiginitio Hospital

Epaminondas Doxakis (✉ edoxakis@bioacademy.gr)  
Biomedical Research Foundation of the Academy of Athens  https://orcid.org/0000-0003-1305-0739

Research

Keywords: microRNA, Parkinson’s disease, biomarkers, plasma

DOI: https://doi.org/10.21203/rs.3.rs-33785/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background There is a pressing need to identify and validate, minimally invasive, molecular biomarkers that will complement current practices and increase the diagnostic accuracy in Parkinson's disease (PD). Brain-enriched miRNAs regulate all aspects of neuron development and function; importantly, they are secreted by neurons in amounts that can be readily detected in the plasma. The aim of the present study was to validate a set of previously identified brain-enriched miRNAs with a diagnostic potential for idiopathic PD and recognize the molecular pathways affected by these deregulated miRNAs.

Methods RT-qPCR was performed in the plasma of 92 healthy controls and 108 idiopathic PD subjects. Statistical and in silico analyses were used to validate deregulated miRNAs and pathways in PD, respectively.

Results miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p and miR-323a-3p levels were found to be differentially expressed between healthy controls and PD patients. miR-330-5p, miR-433-3p and miR-495-3p levels were overall higher in male subjects. Most of these miRNAs are clustered at Chr14q32 displaying CREB1, CEBPB, and MAZ transcription factor binding sites. Gene Ontology (GO) annotation analysis of deregulated miRNA targets revealed that ‘Protein modification’, ‘Transcription factor activity’ and ‘Cell death’ terms were over-represented. Kyoto Encyclopedia of Genes and Genome (KEGG) analysis revealed that ‘Long-term depression’, ‘TGF-beta signaling’, and ‘FoxO signaling’ pathways were significantly affected.

Conclusions We validated a panel of brain-enriched miRNAs that can be used along with other measures for the detection of PD, revealed molecular pathways targeted by these deregulated miRNAs, and identified upstream transcription factors that may be directly implicated in their regulation and thereafter PD pathogenesis.

Background

Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s disease, affects about 1% of people over the age of 60. It is characterized by resting tremor, rigidity, and bradykinesia. In addition, patients with PD display a variety of non-motor symptoms including autonomic disturbances, impaired cognition, depression, and sleep disorders [1]. The neuropathological hallmark of PD is the loss of dopaminergic neurons and the presence of fibrillary aggregates known as Lewy bodies and Lewy neurites in the substantia nigra pars compacta and other brain regions [2]. The aetiology of PD is complex and is believed to arise from the interaction of genes, environmental factors and ageing. While the genetic causes have provided invaluable insights into the pathogenesis, they represent the minority of cases with the remaining resulting from epigenetic changes caused by environmental risk factors and ageing. Intracellular processes that are affected in PD include mitochondrial function, protein folding, proteasomal and autophagy clearance pathways [3].
Diagnosis of PD is currently based on clinical diagnostic criteria and neuroimaging and is monitored by rating scales related to motor and non-motor features [4]. Rating scales are frequently subjective and influenced by periodic fluctuations in symptoms and effective symptomatic therapies, while neuroimaging techniques, such as DAT-SPECT, offer a quantifiable measure of disease progression but are limited by practicality and costs [5]. In addition, protein biomarkers, such as those based on alpha-synuclein (SNCA) and dopamine (DA) metabolic products have yielded mixed results, do not reflect disease progression, and require an invasive lumbar puncture [6].

MicroRNAs (miRNAs) are conserved, ~22 nucleotide RNA molecules that inhibit protein expression by hybridizing to complementary sequences in the 3’ untranslated region (UTR) of target RNA transcripts [7]. Each miRNA is estimated to regulate multiple target mRNAs, and the combinatorial action of miRNAs is expected to regulate the expression of thousands of mRNAs. Although miRNAs act primarily intracellularly, they are secreted by cells for intercellular communication [8] and can be detected in all peripheral fluids including saliva, serum, plasma, CSF and urine. The latter property together with their role in overseeing cellular process makes miRNAs an invaluable tool for disease diagnosis and understanding pathology. Additional advantages of miRNAs over other biomarkers, such as proteins, is that they are stable in bodily fluids [9], many have restricted expression in the tissues they regulate [10], and they are accurately quantified by routine and fast laboratory methods (such as RT-qPCR) that are available in most clinical laboratories. Moreover, clear-cut interpretations can be drawn, as mature miRNA levels generally correlate with miRNA activity, whereas post-translational modifications of proteins confer a complex correlation between activity and expression levels. With respect to PD, the expression levels of many miRNAs are altered in different regions of PD brain or target PD-associated proteins including α-synuclein (SNCA, miR-7 and miR-153) [11] and β-glucocerebrosidase (GBA, miR-22) [12]. Previously, several studies, yet not of a critical mass, have identified deregulated miRNAs in the different biofluids of PD patients. Generally, there is limited overlap between findings due to the source of biofluid used, sample size, methodology, and lack of appropriate controls [13].

Here, we validated the findings of our previous study [14], that had a specific focus on brain-derived miRNAs, using an independent idiopathic PD cohort, and in depth analyzed current and previous data together to reveal not only a panel of deregulated miRNAs but also the upstream and downstream mediators of their effect.

Methods

Study population

The present study included 109 idiopathic PD patients and 92 healthy individuals in two separate cohorts. Patients were assessed with brain magnetic resonance imaging (MRI) or computed tomography (CT) and no relevant brain vascular lesions explaining the clinical phenotype were detected. The control group included spouses or unrelated companions of patients who had no known neurological disease, comorbidities or PD family history. Individuals with concurrent malignant tumors, psychiatric disorders,
collagen diseases, endocrine and cardiovascular diseases, or infections were excluded from this study, since these conditions are expected to alter the expression profile of circulating miRNAs. In addition, patients affected by atypical parkinsonism were also excluded. All patients and controls were recruited from the National and Kapodistrian University of Athens’ neurological unit at Eginition hospital between 2018 and 2019. PD was diagnosed by two neurologists according to Postuma et al. criteria [4]. In all cases, essential demographic and clinical information, including study questionnaire for motor and non-motor manifestations of the disease, rating scales [Hoehn & Yahr (H&Y) stage, mini-mental state examination (MMSE, cognitive impairment score < 26 [15]), and Unified Parkinson's Disease Rating Scale part III (UPDRS III) on or off state] were collected and documented. The demographic and clinical features of patients and controls are summarized in Table 1. Levodopa equivalent daily dose (LEDD) was calculated for the patient groups according to Tomlinson criteria [16].

### Table 1
Demographic and clinical profiles of healthy controls and PD patients.

| Variables                  | Healthy controls | iPD      | p value |
|----------------------------|------------------|---------|---------|
| No of subjects             | 92               | 109     | N/A     |
| Age<sup>a</sup>            | 57.10 ± 12.01    | 64.22 ± 10.41 | < 0.0001 |
| Sex (M/F)                  | 33/59            | 57/52   | < 0.0001 |
| Age of onset<sup>a</sup>   | N/A              | 58.94 ± 11.74 | N/A     |
| Disease duration<sup>a,b</sup> | N/A              | 5.404 ± 5.78   | N/A     |
| UPDRS III<sup>a,c</sup>   | N/A              | 24.19 ± 16.61 | N/A     |
| MMSE<sup>a,d</sup>    | N/A              | 26.87 ± 4.01  | N/A     |

<sup>a</sup> ± SD

<sup>b</sup> Disease duration is counted in years,

<sup>c</sup> Unified Parkinson's Disease Rating Scale

<sup>d</sup> Mini Mental State Examination.

### Plasma collection
Blood processing was carried out according to the Parkinson Progression Marker Initiative (PPMI) protocol. Venous blood was collected in EDTA-treated tubes (BD Vacutainer), followed by immediate centrifugation at 1,500 x g for 5 min at 4 °C. The supernatant plasma was aliquoted to 1 ml per tube and stored at -80 °C until further use.

### miRNA isolation from plasma and RT-qPCR analysis
Plasma samples were thawed at room temperature, centrifuged to pellet any cell debris, and spectrophotometrically analyzed for oxyhemoglobin absorbance at 414 nm. The cut-off level was set at 0.22 against water. Approximately 8.7% and 11.9% of healthy controls and PD plasma samples, respectively, were found hemolyzed and were discarded. miRNA extraction was performed using the NucleoSpin® miRNA plasma kit from Macherey-Nagel. 1 µg of MS2 (Roche) RNA was added to improve miRNA yield during the extraction method. Polyadenylation and reverse transcription reactions were performed in triplicate for every sample. Similarly, qPCR was performed in triplicate on the Roche Lightcycler® 96 using the SYBR FAST Universal 2X qPCR Master Mix from Kapa Biosystems. Stable reference (miR-103a-3p, miR-191-5p, miR-425-5p, miR-223-3p, miR-423-3p) and hemolysis (miR-23a, miR-451a) miRNA controls were included in the plasma analysis and were identical to previous study [14]. Primer sequences can be found in Table 2. The relative expression level of miRNAs was calculated using the $2^{-\Delta\Delta Ct}$ method. Samples with a cycle threshold difference $\Delta(Ct_{23a-3p} - Ct_{451a}) > 5.5$, a PCR-based indicator of hemolysis, were excluded from the final analysis.
| miRNA      | Forward                  | Reverse                                               |
|-----------|--------------------------|-------------------------------------------------------|
| hsa-miR-7-5p | CGCAGTGGAGACTAGTGA       | GTCCAGTTTTTTTTTTTTTTTTTAAAAACA                      |
| hsa-miR-22-3p | GAAGCTGCCAGTTGAAGA     | GTCCAGTTTTTTTTTTTTTTTTTACAGT                       |
| hsa-miR-23a-3p | CATCACATTGCCAGGGAT      | CGTCCAGTTTTTTTTTTTTTTTGGAA                         |
| hsa-miR-103a-3p | GCAGAGCAGATTGTACAG     | GTCCAGTTTTTTTTTTTTTTTTTATAG                       |
| hsa-miR-124-3p | CAGTAAGGCACGCCTGAAGA   | GTCCAGTTTTTTTTTTTTTTTTTGGCATT                      |
| hsa-miR-132-3p | GCAGTAACAGTCTACAGCCA   | GTCCAGTTTTTTTTTTTTTTTTTC                        |
| hsa-miR-136-3p | CGCAGCATTGCACGTCTCA    | GTCCAGTTTTTTTTTTTTTTTTTGAC                       |
| hsa-miR-139-5p | AGTCTACAGTGCACTGTGT    | GTCCAGTTTTTTTTTTTTTTTTTGGAG                      |
| hsa-miR-154-5p | CAGTAGTTATCCGTTTGC    | GTCCAGTTTTTTTTTTTTTTTTTGAAG                      |
| hsa-miR-191-5p | GCAACGGAATCCAAAAGG     | GTCCAGTTTTTTTTTTTTTTTTTACAGCTG                    |
| hsa-miR-223-3p | GCAGTGTCAGTTTGTCAAT   | GTCCAGTTTTTTTTTTTTTTTTTGGTGTA                    |
| hsa-miR-323a-3p | GCAGCAGTTACACGTAGT    | GTCCAGTTTTTTTTTTTTTTTTTAAGGT                      |
| hsa-miR-330-5p | GTCTCTGGGGCTGTCTG    | GTCCAGTTTTTTTTTTTTTTTTTGGCTAAG                     |
| hsa-miR-409-3p | AGGAATGTCGGTCTCGTTG    | GTCCAGTTTTTTTTTTTTTTTTTGGTTAGG                    |
| hsa-miR-423-3p | CGGTCTGGAGGCCTG        | GTCCAGTTTTTTTTTTTTTTTTTGGTTTACTG                  |
| hsa-miR-425-5p | AGAAATGACGGATCAGTCC    | GTCCAGTTTTTTTTTTTTTTTTTTTACAAG                    |
| hsa-miR-433-3p | AGATCAGGTGGCTCCTC      | GTCCAGTTTTTTTTTTTTTTTTTACAC                      |
| hsa-miR-451a-5p | GCAGAAACCGTTACCATTAC  | GTCCAGTTTTTTTTTTTTTTTTTACTCA                     |
**List of miRNAs**

Previously, eight brain-enriched miRNAs were found to be differentially expressed between healthy controls and PD patients [14]. These were miR-7-5p, miR-22-3p, miR-124-3p, miR-136-3p, miR-139-5p, miR-330-5p, miR-433-3p, and miR-495-3p. Four miRNAs that were found to differ in their expression between the two groups, but in a marginal non-significant manner, were also included in the analysis. These were miR-132-3p (p = 0.12), miR-154-5p (p = 0.09), miR-323a-3p (p = 0.13), and miR-409-3p (p = 0.10).

**Statistical analysis**

Statistical analysis was performed using GraphPad PRISM v5.0 and R v3.5.3. All data underwent a normality test (Shapiro–Wilk), and were found to be non-normally distributed. The non-parametric Mann Whitney U test was used to observe differences between healthy controls and PD patients. Spearman’s method, with Bonferroni correction for multiple comparisons, was used to correlate miRNA expression levels with participants’ demographic and clinical characteristics. The threshold for significance was set to p-values less than 0.05.

To assess the possibility that sex is a confounding factor, a two-way ANOVA model was applied to the log-transformed data (normally distributed) with sex as an additional factor. No difference in the miRNAs that were statistically significant was found.

Receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated to evaluate the predictive accuracy/power of plasma miRNAs for PD diagnosis. The cutoff for the ROC analysis was determined using the Youden Index. Data are presented as means ± SEM. miRNA selection was based on the stepwise removal approach. A logistic regression statistical model containing all available miRNAs as independent variables and PD status as the dependent variable was built. Then, the miRNAs with the least contribution in the model (as determined by an F test) were removed. This process continued until no further removals were possible.

**Pathway analysis**

The DIANA mirPath v.3 software suite was used to identify miRNA-regulated pathways. This software renders possible the functional annotation of one or more miRNAs using standard hypergeometric distributions, unbiased empirical distributions and meta-analysis statistics [17]. Here, predicted targets from DIANA microT-CDS algorithm with high quality experimentally supported interactions was used to identify KEGG molecular pathways, as well as GO terms targeted by each miRNA. The combinatorial
effect of deregulated miRNAs was identified by simultaneously selecting multiple miRNAs in the software.

Chromosomal location of miRNAs

Human coordinates for each miRNA were obtained from miRbase release 22.1 website (http://www.mirbase.org/). To visualize data, the coordinates were uploaded on the PhenoGram software which was used to create the chromosomal ideogram [18].

Transcription factors regulating miRNAs

The TransmiR v2.0 literature-curated database of experimentally-validated transcription factors (TF) - miRNA regulations was searched to identify the TFs located 300 bp upstream and 100 bp downstream of each miRNA transcription start site (TSS) [19].

Results

miRNAs are differentially expressed in the plasma of idiopathic PD patients

The demographic and clinical characteristics of 92 healthy controls and 109 idiopathic PD (iPD) patients are summarized in Table 1. RT-qPCR was used to analyze the differential expression of 11 brain-enriched miRNAs [14] and the ubiquitous miR-22-3p that targets GBA mRNA [12] in the plasma of control and PD cohorts. Eight of these miRNAs have been previously identified as significantly deregulated in PD, while four approached statistical significance [14].

Data revealed that 4 out of 12 miRNAs were significantly altered in the plasma obtained from PD patients compared to healthy controls (Fig. 1). These were miR-22-3p, miR-139-5p, miR-154-5p, and miR-330-5p. Table 3 compares the results obtained from previous [14] and current analyses as well as the data when both studies were pooled together. With the exception of miR-139-5p and miR-433-3p that showed reverse expression, the remaining ten miRNAs displayed a very similar expression pattern between the two studies. Pooling the data together, to increase accuracy and statistical power, it was revealed that miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p and miR-323a-3p are differentially expressed between healthy controls and PD patients.
Table 3
Comparative plasma miRNA expression in idiopathic PD patients and healthy controls.

| miRNA expression | Initial study<sup>a</sup> (N: 101 HC, 99 iPD) | Current study (N: 92 HC, 109 iPD) | Pooled data<sup>b</sup> (N: 193 HC, 208 iPD) |
|------------------|------------------------------------------|---------------------------------|---------------------------------|
| miRNA            | Fold change towards healthy controls     | Fold change towards healthy controls | Fold change towards healthy controls |
| miR-7-5p         | 1.276 ± 0.114 p = 0.039                 | 1.158 ± 0.138 p = 0.811         | 1.214 ± 0.090 p = 0.205 |
| miR-22-3p        | 1.180 ± 0.066 p = 0.039                 | 1.307 ± 0.100 p = 0.007         | 1.246 ± 0.061 p = 0.0003 |
| miR-124-3p       | 1.587 ± 0.194 p = 0.006                 | 1.467 ± 0.295 p = 0.198         | 1.524 ± 0.180 p = 0.018 |
| miR-132-3p       | 1.201 ± 0.214 p = 0.392                 | 1.189 ± 0.080 p = 0.171         | 1.195 ± 0.110 p = 0.823 |
| miR-136-3p       | 1.378 ± 0.115 p = 0.004                 | 1.320 ± 0.106 p = 0.088         | 1.347 ± 0.078 p = 0.006 |
| miR-139-5p       | 1.342 ± 0.075 p = 0.0001                | 0.889 ± 0.032 p = 0.021         | 1.104 ± 0.042 p = 0.307 |
| miR-154-5p       | 1.223 ± 0.116 p = 0.111                | 1.312 ± 0.095 p = 0.038         | 1.270 ± 0.074 p = 0.014 |
| miR-323a-3p      | 1.293 ± 0.107 p = 0.018                 | 1.180 ± 0.081 p = 0.147         | 1.234 ± 0.066 p = 0.045 |
| miR-330-5p       | 1.206 ± 0.080 p = 0.042                 | 1.008 ± 0.120 p = 0.028         | 1.101 ± 0.074 p = 0.977 |
| miR-409-3p       | 1.026 ± 0.092 p = 0.814                 | 1.001 ± 0.059 p = 0.620         | 1.013 ± 0.053 p = 0.707 |
| miR-433-3p       | 0.987 ± 0.250 p = 0.964                 | 1.263 ± 0.114 p = 0.438         | 1.132 ± 0.133 p = 0.187 |

Fold change ± SEM towards the mean expression of healthy controls (equals to 1). Statistically significant differences in comparison to healthy controls (Mann Whitney U test) are highlighted in bold.

<sup>a</sup> Original data reported by Ravanidis et al [14].

<sup>b</sup> Pooled data from previous [14] and current studies.
### miRNA expression

| miRNA expression | Initial study<sup>a</sup> (N: 101 HC, 99 iPD) | Current study (N: 92 HC, 109 iPD) | Pooled data<sup>b</sup> (N: 193 HC, 208 iPD) |
|------------------|-----------------------------------------------|--------------------------------|-----------------------------------------------|
| miR-495-3p       | 1.301 ± 0.303 p = 0.424                       | 1.075 ± 0.061 p = 0.459       | 1.183 ± 0.147 p = 0.845                       |

Fold change ± SEM towards the mean expression of healthy controls (equals to 1). Statistically significant differences in comparison to healthy controls (Mann Whitney U test) are highlighted in bold.

<sup>a</sup> Original data reported by Ravanidis et al [14].

<sup>b</sup> Pooled data from previous [14] and current studies.

### Association between miRNA levels and clinical features

Spearman correlation test was used to relate miRNA levels to idiopathic PD patients’ clinical features. We found no correlation between age-at-onset, disease duration, UPDRS III, MMSE, LEDD and miRNA levels, or patients’ on/off state and miRNA levels (Table 4). Furthermore, no difference in the results was observed when data from both studies were pooled together; there was only a weak positive correlation of miR-22-3p with age-at-onset, but this was not significant (p = 0.001) (Supplemental Fig. 1). Finally, correcting clinical scores with LEDD did not reveal any more associations (data not shown).
Table 4
Correlation between relative miRNA expression and age, age-at-onset, PD duration, UPDRS and MMSE scores, and LEDD of PD patients. *Significance level is set at p < 0.0005 after Bonferroni correction.

| Clinical features | Age (Rho (p value)) | Age at onset (Rho (p value)) | PD duration (Rho (p value)) | UPDRS (Rho (p value)) | MMSE (Rho (p value)) | LEDD (Rho (p value)) |
|------------------|---------------------|-----------------------------|---------------------------|----------------------|---------------------|------------------|
| miR-7-5p         | 0.121 (0.082)       | 0.142 (0.041)               | -0.035 (0.617)            | 0.089 (0.203)        | -0.038 (0.582)      | -0.106 (0.127)   |
| miR-22-3p        | 0.285 (<0.001)      | 0.235 (0.001)               | 0.039 (0.577)             | 0.147 (0.034)        | -0.138 (0.047)      | -0.021 (0.765)   |
| miR-124-3p       | 0.263 (<0.001)      | 0.202 (0.004)               | 0.112 (0.107)             | 0.115 (0.098)        | -0.074 (0.286)      | 0.018 (0.8)     |
| miR-132-3p       | 0.036 (0.608)       | 0.057 (0.415)               | 0.01 (0.886)              | 0.061 (0.381)        | -0.109 (0.118)      | 0.028 (0.686)   |
| miR-136-3p       | 0.123 (0.077)       | 0.072 (0.304)               | 0.036 (0.61)              | 0.01 (0.892)         | -0.038 (0.583)      | 0.039 (0.581)   |
| miR-139-5p       | 0.123 (0.076)       | 0.019 (0.791)               | 0.167 (0.016)             | 0.134 (0.054)        | -0.049 (0.48)       | 0.07 (0.316)    |
| miR-154-5p       | 0.1 (0.149)         | 0.062 (0.37)                | -0.012 (0.861)            | -0.001 (0.988)       | -0.01 (0.882)       | 0.059 (0.393)   |
| miR-323a-3p      | 0.11 (0.114)        | 0.102 (0.142)               | -0.036 (0.606)            | 0.008 (0.905)        | -0.045 (0.52)       | 0.004 (0.957)   |
| miR-330-5p       | 0.113 (0.106)       | -0.016 (0.818)              | 0.177 (0.011)             | 0.073 (0.30)         | -0.043 (0.537)      | 0.152 (0.029)   |
| miR-409-3p       | 0.084 (0.233)       | 0.078 (0.268)               | -0.039 (0.579)            | -0.054 (0.441)       | -0.02 (0.776)       | 0.043 (0.537)   |
| miR-433-3p       | 0.091 (0.192)       | 0.122 (0.079)               | 0.027 (0.7)               | 0.079 (0.257)        | -0.135 (0.052)      | 0.084 (0.229)   |
| miR-495-3p       | -0.054 (0.439)      | 0.004 (0.95)                | -0.058 (0.402)            | -0.073 (0.296)       | -0.048 (0.491)      | 0.024 (0.734)   |

Association between miRNA levels and age

There was no significant correlation between miRNA expression and age in either healthy controls or PD patients. When data from both studies were pooled together, miR-22-3p and miR-124-3p showed a positive correlation with age in PD, while miR-136-3p showed a negative correlation with age in healthy controls (Fig. 2A to C). Since both miR-22-3p and miR-124-3p were found upregulated in patients with PD, we performed an analysis of covariance (ANCOVA) with the PD group as a factor and age as a covariate to explore whether these alterations were associated with aging. No differences in these miRNAs between
the ANCOVA and the ordinary analysis of variance (ANOVA) were found. Hence, even in the case where age correlates with miRNA levels, PD pathology has an additional effect on miRNA expression.

**Association between miRNA levels and sex**

We found no significant differences between miRNA relative expression and sex in the present cohort. However, when data from both studies were merged, miR-330-5p, miR-433-3p and miR-495-3p showed higher expression in male subjects (Fig. 3A to C).

**Discriminant Analysis**

To evaluate the utility of plasma miRNA levels in discriminating subjects with PD from healthy controls, ROC curve analysis was performed after merging the data from both studies. The diagnostic sensitivity and specificity of a three-miRNA panel (miR-7-5p, miR-136-3p, miR-409-3p), when age and sex are taken into account, were 72% and 67%, respectively, and the AUC was 0.736 (Fig. 4).

**Pathway analysis**

In order to explore the biological pathways affected by the deregulated brain-enriched miRNAs (pooled data), the DIANA mirPath v3 tool was used to align miRNA predicted targets with KEGG pathways and GOslim categories. Gene union of the deregulated miRNA targets revealed eight KEGG categories as significantly enriched; they included ‘Long-term depression’ (p < 0.00024, 15 genes), ‘TGF-beta signaling pathway’ (p < 0.0017, 17 genes), ‘FoxO signaling pathway’ (p < 0.0059, 29 genes), ‘Estrogen signaling pathway’ (p < 0.011, 18 genes), and ‘ErbB signaling pathway’ (p < 0.011, 20 genes) (Table 5A). Thirteen GOslim categories that are controlled by the gene union of the deregulated miRNA targets were enriched; these included ‘Cellular protein modification’ (p < 2.6e-31, 324 genes), ‘Nucleic acid binding transcription factor activity’ (p < 7.4e-18, 149 genes), ‘Cell death’ (p < 3.2e-08, 115 genes), ‘Catabolic process’ (p < 7.9e-8, 206 genes), and ‘Response to stress’ (p < 0.0003, 221 genes) (Table 5B).
| KEGG pathway                          | p value   | # genes | miRNAs involved                                                                 |
|--------------------------------------|-----------|---------|----------------------------------------------------------------------------------|
| Long-term depression                 | 0.00024   | 15      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                      |
| TGF-beta signaling pathway           | 0.00166   | 17      | miR-22-3p, miR-124-3p, miR-136-3p, miR-323a-3p                                  |
| FoxO signaling pathway               | 0.00594   | 29      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Estrogen signaling pathway           | 0.01093   | 18      | miR-22-3p, miR-124-3p, miR-323a-3p                                            |
| ErbB signaling pathway               | 0.01171   | 20      | miR-22-3p, miR-124-3p, miR-136-3p, miR-323a-3p                                |
| Neurotrophin signaling pathway       | 0.01517   | 25      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                   |
| Amphetamine addiction                | 0.02492   | 12      | miR-22-3p, miR-124-3p, miR-323a-3p                                            |
| Prolactin signaling pathway          | 0.03655   | 16      | miR-22-3p, miR-124-3p, miR-323a-3p                                            |
| GOslim category                                | p value      | # genes | miRNAs involved                                                                 |
|-----------------------------------------------|--------------|---------|--------------------------------------------------------------------------------|
| Cellular protein modification process          | 2.63E-31     | 324     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                      |
| Nucleic acid binding transcription factor activity | 7.43E-18     | 149     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Nucleoplasm                                   | 2.40E-08     | 142     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Cell death                                    | 3.24E-08     | 115     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Catabolic process                             | 7.95E-08     | 206     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Membrane organization                         | 2.14E-07     | 74      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Cytoskeletal protein binding                   | 7.21E-05     | 87      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Response to stress                            | 0.0003       | 221     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| RNA binding                                   | 0.0016       | 187     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Endosome                                      | 0.0032       | 77      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Cell-cell signaling                           | 0.0091       | 66      | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Vesicle-mediated transport                    | 0.0152       | 105     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |
| Immune system process                         | 0.0152       | 150     | miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p                    |

Table 5
KEGG and GOslim categories deregulated in idiopathic PD. Union of the deregulated miRNA (miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p) targets in PD versus (A) KEGG and (B) GOslim
categories created by the DIANA-miRPath v3.0 interface.

**Chromosomal distribution and transcription factors**

Identifying the gene location of the differentially-expressed miRNAs enables a better understanding of their regulation of expression and association with putative chromosomal abnormalities previously linked with these regions. To assess this parameter, the chromosomal coordinates of miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p, miR-323a-3p, miR-330-5p, miR-433-3p, and miR-495-3p were collected from miRbase 22.1 and visualized using Phenogram (Fig. 5A). Interestingly, five of these miRNAs (miR-136-3p, miR-154-5p, miR-323a-3p, miR-433-3p, and miR-495-3p) were clustered at the same location on chromosome 14q32, suggesting that they are co-regulated by specific transcription factors or methylation.

To identify the transcription factors regulating the differentially-expressed miRNAs, the manually curated TransmiR v2.0 experimental database was used with highly stringent parameters to locate TF sites downstream of each miRNA transcription start site. The analysis revealed that TF binding sites for cAMP responsive element binding protein 1 (CREB1), CCAAT enhancer binding protein beta (CEBPB) and MYC associated zinc finger protein (MAZ) were found in over half of the miRNAs, including all five miRNAs located on Chr14 (Fig. 5B).

**Discussion**

We previously reported that brain-enriched miRNAs can differentiate healthy controls from genetic and idiopathic PD subjects [14]. Here, we report results of an equally large validation study conducted on twelve miRNAs that were significantly or marginally non-significantly altered in our original study. With the exception of two miRNAs, miR-139-5p and miR-433-3p, all other miRNAs displayed very similar expression patterns and differences between healthy control and PD subjects in both studies. Combining the data, it was revealed that miR-22-3p, miR-124-3p, miR-136-3p, miR-154-5p and miR-323a-3p are differentially expressed between healthy controls and PD subjects. Of these, miR-22-3p [20–22], miR-124-3p [23], and miR-136-3p [21, 24] have been identified as deregulated in other PD biomarker studies, further validating current findings and their replicability at different neurological centers.

There is considerable information regarding the biological role of some of these deregulated miRNAs. miR-22-3p targets GBA, which encodes for β-glucocerebrosidase, a lysosomal enzyme involved in sphingolipid degradation; mutations in GBA are the single largest risk factor for PD [25]. In addition, miR-22 is neuroprotective in multiple neurodegeneration and traumatic brain injury models, has regenerative capabilities, and is involved in several aspects of neuronal development including cell cycle length, polarization of migrating neurons, and long-term synaptic plasticity [26–28]. miR-124-3p is the most abundant neuronal miRNA in the nervous system, and is considered indispensable for neuronal fate determination, differentiation, and plasticity [29, 30]. It is anti-inflammatory and protects dopaminergic neurons from MPTP- and 6-OHDA-induced toxicity via multiple pathways [31]. Less is known about miR-136-3p, miR-154-5p, and miR-323a-3p. miR-136-3p expression is upregulated in synaptoneurosomes at
preclinical stage of prion disease and its overexpression protects cells from neuroinflammation following ischemic insults [32, 33]. miR-154-5p is differentially regulated during morphine self-administration and is predicted to have an important role in dopaminergic neuron differentiation and mu-opioid receptor regulation [34]. miR-323a-3p is upregulated in mild cognitive impairment, and differentially regulated by 6-OHDA and ischemia/reperfusion injury [35, 36]. Importantly, we found that all five deregulated miRNAs are significantly increased in PD; the fact that most of these miRNAs appear to have strong neuroprotective properties at multiple settings, may suggest that they are regulated as a compensatory response to brain impairment.

Men have fifty percent higher incidence of PD [37] and, interestingly, we found that the expression of three brain-enriched miRNAs, miR-330-5p, miR-433-3p and miR-495-3p was significantly higher in male subjects. Considering that the ratio of males to women was different in our two studies, we think that this partly explains the inconsistency in miR-433-3p expression between them. Little is known of their biological roles. miR-330-5p targets mRNAs involved in activity-dependent synaptic plasticity in the hippocampus [38]. miR-433-3p targets follicle-stimulating hormone (FSH) expression in the anterior pituitary, and HIF1α levels in the brain during hypoxia inhibiting neuron proliferation and migration [39, 40]. miR-495-3p targets are enriched for addiction and pro-survival genes, including BDNF, CAMK2 and ARC [41]. Furthermore, miR-495-3p expression is upregulated following deep brain stimulation [42]. Collectively, it is documented that these three miRNAs have rather negative impact on neuronal processes affected in PD, however, further work is required to better delineate their roles, and if/how their higher expression in males affects vulnerability to PD.

Examining the chromosomal coordinates of the differentially-expressed brain miRNAs, we found that miR-136-3p, miR-154-5p, miR-323a-3p, miR-433-3p, and miR-495-3p are located on Chr14q32, suggesting that they are co-deregulated by transcription factors or methylation. This area is inherently unstable and a 1.1 Mb microdeletion (14q32.2.q32.3, coordinates Chr14: ~100,400,000 -101,500,000) has been reported in a number of patients displaying motor delay, hypotonia, and feeding problems [43, 44]. This genomic rearrangement is thought to be generated after the 500 bp expanded repeats flanking the deletion boundaries undergo either non-allelic homologous recombination (NAHR) or form secondary structures that interfere with normal DNA replication and chromosome condensation [43]. It should be noted that the particular location also hosts fifteen protein coding genes, some of which are imprinted [43, 44]. More recently, miRNAs of this cluster were found to be among the most longitudinally stable miRNAs, indicating that they are ideal biomarkers to monitor the progression pathophysiological states including PD, reiterating the importance of the current findings [45]. Moreover, we have used the TransmiR v2 experimental, manually curated, database to probe the TFs that regulate the expression of these deregulated brain miRNAs. Transcription binding sites for CREB1, CEBPB and MAZ were found in all miRNAs located at Chr14q32. In addition, a CREB1 site was found at miR-22 gene locus. CREB1 is essential for neuronal survival and axonal growth via both transcription of neurotrophins and neurotrophin-dependent CREB1-mediated transcription of pro-survival genes [46]. CREB1 is also required for adult neurogenesis, synaptic plasticity and memory formation [47, 48]. Similarly to CREB1, CEBPB has been implicated in the control of neuronal development and survival, including processes such as cell
fate determination, synthesis and response to trophic factors, learning, and memory [49, 50]. MAZ on the other hand, has been linked to neural stem cell differentiation towards the glial cell lineage [51] and the induction of the NMDA receptor subunit type 1 (NR1) gene after neuronal differentiation [52]. Overall, these data indicate that epigenetic deregulation at Chr14q32 locus maybe responsible or contribute to neuronal miRNA differential expression in PD.

To explore the molecular pathways controlled by the deregulated miRNAs, in silico analysis of KEGG pathways and GO terms was performed. KEGG categories such as 'Long-term depression', 'TGF-beta signaling pathway', 'FoxO signaling pathway', 'Estrogen signaling pathway', 'ErbB signaling pathway', and 'Neurotrophin signaling pathway', that are implicated in PD- associated processes, particularly dopaminergic neuron development and survival, were over-represented [53–60]. 'Cellular protein modification', 'Nucleic acid binding transcription factor activity', 'Cell death', 'Catabolic process', were overrepresented among the biological processes affected. Cellular protein modifications such as phosphorylation, ubiquitination, truncation, acetylation, nitration and sumoylation of PD-linked proteins have emerged as important modulators of pathogenic mechanisms in PD [61, 62]. Transcription factor changes are also of particular interest, as they indicate that there is not only misexpression at the mRNA translation level by miRNA deregulation, but that there exists a second wave of en masse deregulation involving transcription-wide changes. Recently, we have integrated data across twenty-four PD biomarker studies and identified 25 miRNAs reported deregulated in at least two studies [13]. Five of the currently reported deregulated miRNAs are found in that list. Interestingly, following stringent bioinformatic analysis and different bioinformatic tools to the ones used in the current manuscript [TargetScan 7.2 for miRNA target prediction in conjunction with DAVID v6.8 for pathway analysis as opposed to DIANA mirPath v.3 used here], revealed that all top four GO categories controlled by the 25 deregulated miRNAs were likewise associated with transcription factors. Hence, it appears that transcription factor misexpression is an important component of miRNA deregulation in PD.

**Conclusions**

We performed an RT-qPCR analysis of brain-derived miRNAs in the plasma of a relatively large cohort of patients with PD and matched controls to replicate and validate previous findings. The identified miRNAs form a robust set of deregulated brain-associated miRNAs in PD, that can now be further evaluated, along with other measures, as diagnostic and therapeutic tools for PD. Importantly, existing information of their neurological functions provides a clue of the processes they regulate during PD. In silico analysis provided a comprehensive guide of the pathways and processes they control, improving current understanding of their biological role. Further, Chr14q32 turns out to be a hotspot of these deregulated miRNAs. Importantly, they are co-transcribed by specific transcription factors that regulate neuronal survival, memory and plasticity in the adult brain. The impact of the latter findings will now await further exploration.

**Abbreviations**
ANCOVA, analysis of covariance; ANOVA, analysis of variance; AUC, area under the curve; CEBPB, CCAAT enhancer binding protein beta; CREB1, cAMP responsive element binding protein 1; CT, computed tomography; FSH, follicle-stimulating hormone; GBA, Beta-Glucocerebrosidase; GO, Gene Ontology; HC, healthy control; H&Y, Hoehn & Yahr; iPD, idiopathic PD; KEGG, Kyoto encyclopedia of genes and genomes; LEDD, Levodopa equivalent daily dose; MAZ, MYC associated zinc finger protein; MMSE, Mini Mental State Examination; MRI, magnetic resonance imaging; PD, Parkinson's disease; SNCA, alpha-synuclein TF, transcription factor; UPDRS, Unified Parkinson's Disease Rating Scale; UTR, untranslated region.

**Declarations**

**AUTHORS’ CONTRIBUTIONS**

Conceived the study: ED. Organized the study: ED, LS. Collected blood samples and neurologically examined patients: AB, CK, AMS, IP, MB. Designed and optimized protocols: ED. Performed RNA extraction and PCR experiments: SR. Analyzed data: SR, NP, ED. *In silico* analyses: ED. Wrote the manuscript: ED. All authors read, edited and approved the final manuscript.

**ACKNOWLEDGMENTS**

The authors are grateful to patients, relatives and volunteer healthy controls for their participation in this study.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

The Hospital and BRFAA ethics committees approved the study and all participants provided written consent.

**FUNDING**

This work was supported by the Michael J. Fox Foundation for Parkinson's Research (Grant ID 13353).

**AVAILABILITY OF DATA**

The datasets analysed during the current study are available from the corresponding author on reasonable request.

**COMPETING INTERESTS**

The authors declare that they have no competing interests.
CONSENT FOR PUBLICATION
Not applicable

References

1. Sveinbjörnsdóttir S: The clinical symptoms of Parkinson's disease. *Journal of neurochemistry* 2016, **139 Suppl** 1:318-324.

2. Dickson DW: Neuropathology of Parkinson disease. *Parkinsonism & related disorders* 2018, **46 Suppl 1**:S30-S33.

3. Klein C, Schlossmacher MG: Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. *Neurology* 2007, **69**(22):2093-2104.

4. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE et al: MDS clinical diagnostic criteria for Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2015, **30**(12):1591-1601.

5. Bhidayasiri R, Martinez-Martin P: Clinical Assessments in Parkinson's Disease: Scales and Monitoring. *International review of neurobiology* 2017, **132**:129-182.

6. Miller DB, O'Callaghan JP: Biomarkers of Parkinson's disease: present and future. *Metabolism: clinical and experimental* 2015, **64**(3 Suppl 1):S40-46.

7. Doxakis E: Principles of miRNA-Target Regulation in Metazoan Models. *International journal of molecular sciences* 2013, **14**(8):16280-16302.

8. Chen X, Liang H, Zhang J, Zen K, Zhang CY: Secreted microRNAs: a new form of intercellular communication. *Trends in cell biology* 2012, **22**(3):125-132.

9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al: Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences of the United States of America* 2008, **105**(30):10513-10518.

10. Jovicic A, Roshan R, Moisoi N, Pradervand S, Moser R, Pillai B, Luthi-Carter R: Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2013, **33**(12):5127-5137.

11. Doxakis E: Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. *The Journal of biological chemistry* 2010, **285**(17):12726-12734.

12. Straniero L, Rimoldi V, Samarani M, Goldwurm S, Di Fonz A, Kruger R, Deleidi M, Aureli M, Solda G, Duga S et al: The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. *Scientific reports* 2017, **7**(1):12702.

13. Doxakis E: Cell-free microRNAs in Parkinson's disease: potential biomarkers that provide new insights into disease pathogenesis. *Ageing research reviews* 2020, **58**:101023.
14. Ravanidis S, Bougea A, Papagiannakis N, Maniati M, Koros C, Simitsi AM, Bozi M, Pachi I, Stamelou M, Paraskevas GP et al: Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 2019.

15. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S et al: Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Movement disorders : official journal of the Movement Disorder Society 2007, 22(16):2314-2324.

16. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE: Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 2010, 25(15):2649-2653.

17. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG: DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic acids research 2015, 43(W1):W460-466.

18. Wolfe D, Dudek S, Ritchie MD, Pendergrass SA: Visualizing genomic information across chromosomes with PhenoGram. BioData mining 2013, 6(1):18.

19. Tong Z, Cui Q, Wang J, Zhou Y: TransmiR v2.0: an updated transcription factor-microRNA regulation database. Nucleic acids research 2019, 47(D1):D253-D258.

20. Dos Santos MCT, Barreto-Sanz MA, Correia BRS, Bell R, Widnall C, Perez LT, Berteau C, Schulte C, Scheller D, Berg D et al: miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. Oncotarget 2018, 9(25):17455-17465.

21. Gui Y, Liu H, Zhang L, Lv W, Hu X: Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 2015, 6(35):37043-37053.

22. Margis R, Margis R, Rieder CR: Identification of blood microRNAs associated to Parkinson's disease. Journal of biotechnology 2011, 152(3):96-101.

23. Li N, Pan X, Zhang J, Ma A, Yang S, Ma J, Xie A: Plasma levels of miR-137 and miR-124 are associated with Parkinson's disease but not with Parkinson's disease with depression. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2017, 38(5):761-767.

24. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C, Sabbagh M, Villa S et al: Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PloS one 2014, 9(5):e94839.

25. Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, Pollak P, Bonaiti B, Bonaiti-Pellie C, Brice A et al: Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012, 78(6):417-420.

26. Fiumara F, Rajasethupathy P, Antonov I, Kosmidis S, Sossin WS, Kandel ER: MicroRNA-22 Gates Long-Term Heterosynaptic Plasticity in Aplysia through Presynaptic Regulation of CPEB and
Downstream Targets. *Cell reports* 2015, 11(12):1866-1875.

27. Volvert ML, Prevot PP, Close P, Laguesse S, Pirotte S, Hemphill J, Register F, Kruzy N, Sacheli R, Moonen G et al: MicroRNA targeting of CoREST controls polarization of migrating cortical neurons. *Cell reports* 2014, 7(4):1168-1183.

28. Yang CP, Zhang ZH, Zhang LH, Rui HC: Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7. *Journal of molecular neuroscience : MN* 2016, 60(4):445-452.

29. Rajasethupathy P, Fiumara F, Sheridan R, Betel D, Puthanveettil SV, Russo JJ, Sander C, Tuschi T, Kandel E: Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. *Neuron* 2009, 63(6):803-817.

30. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, Lee-Messer C, Dolmetsch RE, Tsien RW, Crabtree GR: MicroRNA-mediated conversion of human fibroblasts to neurons. *Nature* 2011, 476(7359):228-231.

31. Wang H, Ye Y, Zhu Z, Mo L, Lin C, Wang Q, Wang H, Gong X, He X, Lu G et al: MiR-124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim. *Brain Pathol* 2016, 26(2):167-176.

32. Boese AS, Saba R, Campbell K, Major A, Medina S, Burton L, Booth TF, Chong P, Westmacott G, Dutta SM et al: MicroRNA abundance is altered in synaptoneurosomes during prion disease. *Molecular and cellular neurosciences* 2016, 71:13-24.

33. Zhong Y, Yu C, Qin W: LncRNA SNHG14 promotes inflammatory response induced by cerebral ischemia/reperfusion injury through regulating miR-136-5p/ROCK1. *Cancer gene therapy* 2019, 26(7-8):234-247.

34. Tapocik JD, Luu TV, Mayo CL, Wang BD, Doyle E, Lee AD, Lee NH, Elmer GI: Neuroplasticity, axonal guidance and micro-RNA genes are associated with morphine self-administration behavior. *Addiction biology* 2013, 18(3):480-495.

35. Li L, Chen HZ, Chen FF, Li F, Wang M, Wang L, Li YQ, Gao DS: Global microRNA expression profiling reveals differential expression of target genes in 6-hydroxydopamine-injured MN9D cells. *Neuromolecular medicine* 2013, 15(3):593-604.

36. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR: Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. *Aging* 2013, 5(12):925-938.

37. Hirsch L, Jette N, Frolikis A, Steeves T, Pringsheim T: The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Neuroepidemiology* 2016, 46(4):292-300.

38. Cohen JE, Lee PR, Fields RD: Systematic identification of 3′-UTR regulatory elements in activity-dependent mRNA stability in hippocampal neurons. *Philosophical transactions of the Royal Society of London Series B, Biological sciences* 2014, 369(1652).

39. Han DX, Sun XL, Xu MQ, Chen CZ, Jiang H, Gao Y, Yuan B, Zhang JB: Roles of differential expression of microRNA-21-3p and microRNA-433 in FSH regulation in rat anterior pituitary cells. *Oncotarget* 2017, 8(22):36553-36565.
40. Zhang L, Zhang Y, Zhang X, Zhang Y, Jiang Y, Xiao X, Tan J, Yuan W, Liu Y: MicroRNA-433 Inhibits the Proliferation and Migration of HUVECs and Neurons by Targeting Hypoxia-Inducible Factor 1 Alpha. *Journal of molecular neuroscience : MN* 2017, **61**(2):135-143.

41. Bastle RM, Oliver RJ, Gardiner AS, Pentkowski NS, Bolognani F, Allan AM, Chaudhury T, St Peter M, Galles N, Smith C et al: *In silico* identification and *in vivo* validation of miR-495 as a novel regulator of motivation for cocaine that targets multiple addiction-related networks in the nucleus accumbens. *Molecular psychiatry* 2018, **23**(2):434-443.

42. Puig-Parnau I, Garcia-Brito S, Faghihi N, Gubern C, Aldavert-Vera L, Segura-Torres P, Huguet G, Kadar E: Intracranial Self-Stimulation Modulates Levels of SIRT1 Protein and Neural Plasticity-Related microRNAs. *Molecular neurobiology* 2020.

43. Bena F, Gimelli S, Migliavacca E, Brun-Druc N, Buiting K, Antonarakis SE, Sharp AJ: A recurrent 14q32.2 microdeletion mediated by expanded TGG repeats. *Human molecular genetics* 2010, **19**(10):1967-1973.

44. Zada A, Mundhofir FE, Pfundt R, Leijsten N, Nillesen W, Faradz SM, de Leeuw N: A Rare, Recurrent, De Novo 14q32.2q32.31 Microdeletion of 1.1 Mb in a 20-Year-Old Female Patient with a Maternal UPD(14)-Like Phenotype and Intellectual Disability. *Case reports in genetics* 2014, **2014**:530134.

45. Valbuena GN, Apostolidou S, Roberts R, Barnes J, Alderton W, Harper L, Jacobs I, Menon U, Keun HC: The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. *Scientific reports* 2019, **9**(1):15787.

46. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, Tronche F, Kellendonk C, Gau D, Kapfhammer J et al: Disruption of CREB function in brain leads to neurodegeneration. *Nature genetics* 2002, **31**(1):47-54.

47. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ: Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. *Cell* 1994, **79**(1):59-68.

48. Kogan JH, Frankland PW, Blendy JA, Coblentz J, Marowitz Z, Schutz G, Silva AJ: Spaced training induces normal long-term memory in CREB mutant mice. *Current biology : CB* 1997, **7**(1):1-11.

49. Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, Yonan AL, Vronskaya S, Grody MB, Cepeda I et al: Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. *Neuron* 2003, **39**(4):655-669.

50. Paquin A, Barnabe-Heider F, Kageyama R, Miller FD: CCAAT/enhancer-binding protein phosphorylation biases cortical precursors to generate neurons rather than astrocytes in vivo. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2005, **25**(46):10747-10758.

51. Liu B, Ma A, Zhang F, Wang Y, Li Z, Li Q, Xu Z, Zheng Y: MAZ mediates the cross-talk between CT-1 and NOTCH1 signaling during gliogenesis. *Scientific reports* 2016, **6**:21534.

52. Okamoto S, Sherman K, Bai G, Lipton SA: Effect of the ubiquitous transcription factors, SP1 and MAZ, on NMDA receptor subunit type 1 (NR1) expression during neuronal differentiation. *Brain*
research Molecular brain research 2002, 107(2):89-96.

53. Hegarty SV, Sullivan AM, O’Keeffe GW: Roles for the TGFbeta superfamily in the development and survival of midbrain dopaminergic neurons. Molecular neurobiology 2014, 50(2):559-573.

54. Roussa E, Wiehle M, Dunker N, Becker-Katins S, Oehlke O, Krieglstein K: Transforming growth factor beta is required for differentiation of mouse mesencephalic progenitors into dopaminergic neurons in vitro and in vivo: ectopic induction in dorsal mesencephalon. Stem Cells 2006, 24(9):2120-2129.

55. Zhang J, Pho V, Bonasera SJ, Holtzman J, Tang AT, Hellmuth J, Tang S, Janak PH, Tecott LH, Huang EJ: Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. Nature neuroscience 2007, 10(1):77-86.

56. Andrews ZB, Zhao H, Frugier T, Meguro R, Grattan DR, Koishi K, McLennan IS: Transforming growth factor beta2 haploinsufficient mice develop age-related nigrostriatal dopamine deficits. Neurobiology of disease 2006, 21(3):568-575.

57. Tesseur I, Nguyen A, Chang B, Li L, Woodling NS, Wyss-Coray T, Luo J: Deficiency in Neuronal TGF-beta Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-beta Signaling Protects against MPTP Neurotoxicity in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 2017, 37(17):4584-4592.

58. Iwakura Y, Piao YS, Mizuno M, Takei N, Kakita A, Takahashi H, Nawa H: Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson’s disease and its model: neurotrophic implication in nigrostriatal neurons. Journal of neurochemistry 2005, 93(4):974-983.

59. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T et al: A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 2006, 8(8):834-842.

60. Skirzewski M, Karavanova I, Shamir A, Erben L, Garcia-Olivares J, Shin JH, Vullhorst D, Alvarez VA, Amara SG, Buonanno A: ErbB4 signaling in dopaminergic axonal projections increases extracellular dopamine levels and regulates spatial/working memory behaviors. Molecular psychiatry 2018, 23(11):2227-2237.

61. Junqueira SC, Centeno EGZ, Wilkinson KA, Cimarosti H: Post-translational modifications of Parkinson’s disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination. Biochimica et biophysica acta Molecular basis of disease 2019, 1865(8):2001-2007.

62. Pajarillo E, Rizor A, Lee J, Aschner M, Lee E: The role of posttranslational modifications of alpha-synuclein and LRRK2 in Parkinson’s disease: Potential contributions of environmental factors. Biochimica et biophysica acta Molecular basis of disease 2019, 1865(8):1992-2000.

Figures
Figure 1

Scatter plots of miRNA relative expression in the plasma of healthy control and idiopathic PD groups. Graphs show mean levels +/- SEM. Non-parametric Mann Whitney U test was used to determine the significance of differences between the two groups (p-values in the box next to each corresponding graph). *p<0.05, **p<0.01, ***p<0.001.
Figure 1

Scatter plots of miRNA relative expression in the plasma of healthy control and idiopathic PD groups. Graphs show mean levels +/- SEM. Non-parametric Mann Whitney U test was used to determine the significance of differences between the two groups (p-values in the box next to each corresponding graph). *p<0.05, **p<0.01, ***p<0.001.
Figure 2

miR-22-3p, miR-124-3p, and miR-136-3p levels correlate with aging. Scatter plot of (A) miR-22-3p and (B) miR-124-3p correlation with ageing in PD. (C) miR-136-3p correlation with ageing in healthy controls. Data are Spearman r-values with p<0.0005.
miR-330-5p, miR-433-3p and miR-495-3p levels are higher in male subjects. Plot of (A) miR-330-5p, (B) miR-433-3p, and (C) miR-495-3p and sex. *p<0.05.
Figure 4

The receiver operating characteristic (ROC) curve analysis for discriminating idiopathic PD from healthy control subjects. ROC curve of miR-7-5p, miR-136-3p, and miR-409-3p when age and sex are taken into account differentiates iPD from HC cases. AUC, area under the curve.
Figure 4

The receiver operating characteristic (ROC) curve analysis for discriminating idiopathic PD from healthy control subjects. ROC curve of miR-7-5p, miR-136-3p, and miR-409-3p when age and sex are taken into account differentiates iPD from HC cases. AUC, area under the curve.
| miRNA       | Chromosomal coordinates         |
|-------------|---------------------------------|
| miR-433-3p  | chr14: 100881886-100881978 [+]  |
| miR-136-3p  | chr14: 100884702-100884783 [+]  |
| miR-323a-3p | chr14: 101025732-101025817 [+]  |
| miR-495-3p  | chr14: 101033755-101033836 [+]  |
| miR-154-5p  | chr14: 101059755-101059838 [+]  |

### B

| Transcription factor | miRNA<sup>a</sup>                      |
|----------------------|-----------------------------------------|
| CREB1                | miR-22, miR-136, miR-154, miR-323a, miR-433, miR-495 |
| CEBPB                | miR-136, miR-154, miR-323a, miR-433, miR-495 |
| MAZ                  | miR-136, miR-154, miR-323a, miR-433, miR-495 |
| HNF4A                | miR-124, miR-154, miR-495                |
|       | miRNAs          |
|-------|----------------|
| REST  | miR-22, miR-124, miR-330 |
| EGR1  | miR-22, miR-124 |
| ERG   | miR-22, miR-330 |
| HDAC1 | miR-22, miR-124 |
| MYCN  | miR-22, miR-330 |
| SMAD3 | miR-136, miR-433 |
| STAT1 | miR-22, miR-124 |
| STAT3 | miR-22, miR-124 |
| TP53  | miR-22, miR-124 |

**Figure 5**

Chromosomal distribution of deregulated miRNAs and transcription factor sites. (A) Phenogram of deregulated miRNAs in PD and chromosomal coordinates of deregulated miRNAs in PD. (B) Transcription factors that control the expression of deregulated miRNAs in PD.
### A

![Genetic Chromosome Diagram](image)

### Table: miRNA and Chromosomal Coordinates

| miRNA          | Chromosomal coordinates                  |
|----------------|------------------------------------------|
| miR-433-3p     | chr14: 100881886-100881978 [+ ]         |
| miR-136-3p     | chr14: 100884702-100884783 [+ ]         |
| miR-323a-3p    | chr14: 101025732-101025817 [+ ]         |
| miR-495-3p     | chr14: 101033755-101033836 [+ ]         |
| miR-154-5p     | chr14: 101059755-101059838 [+ ]         |

### B

| Transcription factor | miRNA<sup>a</sup>                      |
|----------------------|----------------------------------------|
| CREB1                | miR-22, miR-136, miR-154, miR-323a, miR-433, miR-495 |
| CEBPB                | miR-136, miR-154, miR-323a, miR-433, miR-495 |
| MAZ                  | miR-136, miR-154, miR-323a, miR-433, miR-495 |
| HNF4A                | miR-124, miR-154, miR-495               |
| REST    | miR-22, miR-124, miR-330 |
|---------|------------------------|
| EGR1    | miR-22, miR-124        |
| ERG     | miR-22, miR-330        |
| HDAC1   | miR-22, miR-124        |
| MYCN    | miR-22, miR-330        |
| SMAD3   | miR-136, miR-433       |
| STAT1   | miR-22, miR-124        |
| STAT3   | miR-22, miR-124        |
| TP53    | miR-22, miR-124        |

**Figure 5**

Chromosomal distribution of deregulated miRNAs and transcription factor sites. (A) Phenogram of deregulated miRNAs in PD and chromosomal coordinates of deregulated miRNAs in PD. (B) Transcription factors that control the expression of deregulated miRNAs in PD.